OKYO Pharma (“OKYO” or the “Company”) – announces two presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
- OK-101 improves neuropathic corneal pain in a mouse model of ciliary nerve ligation
- Peptide Analog BAM8-22 OK-201 Relieves Neuropathic Corneal Pain in Mice
LONDON, April 27, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of new molecules to treat inflammatory dry eye disease and eye pain, today announced that two presentations will be given on OKYO drug candidates OK-101 and OK-201 at the Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting, to be held May 1-4, 2022 in Denver, CO and virtually May 11-12 2022.
The oral presentation will demonstrate the ability of OK-101, a novel ChemR23 chemerin receptor agonist, to reduce neuropathic corneal pain (PCN) in a mouse model of ciliary nerve ligation; and the second presentation, which will be given as a poster, will present the efficacy data of OK-201, an analogue of the BAM8-22 peptide, in the relief of neuropathic corneal pain in the same mouse model. These studies were conducted in collaboration with Pedram Hamrah, MD, acting chair of ophthalmology, corneal specialist, and clinician-scientist at Tufts Medical Center, Boston, MA, using a mouse model of NCP developed in Dr. Hamrah’s lab.
The presentation details are as follows:
Presentation type: paper session
Presentation number: 1834
Title: OK-101, a novel chemerin receptor agonist, improves neuropathic corneal pain in a mouse model of ciliary nerve ligation
Presenter: Harris, Deshea, Department of Ophthalmology, Tufts Medical Center, Boston, MA
Presentation date and time: May 2, 2022, 4:08 p.m. to 4:25 p.m. MDT
Presentation Type: Poster Session
Bulletin board number: 1227 – A0227
Title: Peptide analogue BAM8-22 derived from proenkephalin relieves neuropathic corneal pain in mice
Presenter: Ayesha Sultan, Department of Ophthalmology, Tufts Medical Center, Boston, MA
Poster Session Date/Time: May 2, 2022, 10:00 a.m. to 12:00 p.m. MDT
OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) is a life sciences and biotechnology company admitted to listing on the Standard Segment of the UK Financial Conduct Authority’s official list and to trading on the Main Securities Market. listed on the London Stock Exchange. plc. OKYO focuses on the discovery and development of new molecules to treat inflammatory dry eye disease and eye pain.
About eye pain
Eye pain is one of the most common causes for referral of patients to the emergency clinic, with significant implications for overall quality of life and healthcare cost. Millions of people suffer from eye pain each year without any treatment approved by the United States Food and Drug Administration for this condition. Side effects and the risk of opioid addiction are a serious concern. Eye pain can result directly from tissue damage to the ocular surface after surgery, injury, infection, or changes to the peripheral or central ocular surface nerves. Neuropathic ocular pain refers to the increased perception of pain in response to usually nonpainful stimuli and is often misdiagnosed as dry eye disease. Current treatments are limited to short-term nonsteroidal anti-inflammatory drugs, steroids and gabapentin, and oral opioids in severe cases.
OK-101 is a novel long-acting G-protein-coupled receptor lipid chemerin peptide developed to bind to ChemR23 receptors commonly found on immunological cells found in the eye. ChemR23 plays an important role in the inflammatory response, and binding of OK-101 to ChemR23 has been shown to produce anti-inflammatory activity in mouse models of dry eye. OK-101 was developed using membrane-anchored peptide (MAP) technology to produce a long-acting drug candidate designed to combat washout through the inclusion of a lipid ‘anchor’ in its molecular structure to improve the residence time on the ocular surface.
MAS-Related G Protein-Coupled Receptors, or MRGPRs, mainly expressed in sensory neurons, are involved in pain perception, making them a promising analgesic target. Activation of MRGPR by bovine adrenal medulla, or BAM, peptide inhibits pain perception by modulating Ca2+ influx. OK-201, a BAM peptide analog, is a potent human MRGPR agonist and a promising candidate for the treatment of neuropathic and inflammatory pain.
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates and projections regarding its industry; his beliefs; and assumptions. Words such as “anticipates”, “expects”, “intends”, “plans”, “believes”, “seeks”, “estimates” and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the Company’s control, are difficult to predict and could cause actual results differ materially from those expressed or anticipated. in forward-looking statements. The Company cautions securityholders and potential securityholders not to place undue reliance on these forward-looking statements, which reflect the Company’s views only as of the date of this announcement. Forward-looking statements made in this announcement relate only to events as of the date the statements are made. The Company undertakes no obligation to publicly release revisions or updates to these forward-looking statements to reflect unforeseen events, circumstances or developments occurring after the date of this announcement, except as required by law or any applicable regulatory authority. ‘required.
For more information, please visit the Company’s website at www.okyopharma.com.